Francesco Bandello
Francesco Bandello is an expert in Ophthalmology at IRCCS Ospedale San Raffaele (Italy). As of October 2026, ScienceLeadR ranks Francesco Bandello in the top 1% of experts worldwide for Retinal Diseases, Eye Injuries and Retinal Vein Occlusion. Francesco Bandello has authored 1,454 publications, the most recent in 2026, and is an investigator in 45 clinical trials, 12 of them ongoing. SLR score: 5,128 (community average: 125). How the SLR is computed.
LeadR Profile
Ophthalmology
Subspecialties: Surgery - Medical Imaging - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1990 - 2026
Number : 1454
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Spontaneous Regression of Vitreoretinal Lymphoma Lesions: Case Series and Literature Review. PMID 42770730 — lymphoma, multimodal imaging, therapeutics, wounds and injuries | Ocul Immunol Inflamm | 2026 | 0 |
| White dot syndromes in the era of multimodal imaging. PMID 42720431 — white dot syndromes, eye injuries, multimodal imaging, eye diseases, therapeutics, retinaldehyde | Eur J Ophthalmol | 2026 | 0 |
| Aflibercept 8 mg for diabetic macular edema and neovascular age-related macular degeneration: an italian expert consensus paper. PMID 42684442 — macular degeneration, treatment adherence and compliance, ophthalmology, macular edema, therapeutics, edema | Graefes Arch Clin Exp Ophthalmol | 2026 | 0 |
| Natural History of Macular Sensitivity in Best Vitelliform Macular Dystrophy: Microperimetry-Derived Outcome Measures in Preparation For Clinical Trials. PMID 42678224 — eye, macular degeneration, natural history, ophthalmology, scotoma, history, vitelliform macular dystrophy | Invest Ophthalmol Vis Sci | 2026 | 0 |
| Long-Term Graft Survival Following Penetrating Keratoplasty in Eyes with Preoperative Corneal Neovascularization. PMID 42671781 — eye, corneal transplantation, graft survival, corneal neovascularization, keratoplasty, penetrating, transplants | Ophthalmol Ther | 2026 | 0 |
Clinical Studies 45
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 4
Ongoing Clinical Trials
12 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A clinical trial of EYE201 MK 8748 in people with macular degeneration (MK 8748 003) 2025-524894-17-00 — macular degeneration, safety | Phase 2/Phase 3 | Recruiting | 2026 |
| Long term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age related Macular Degeneration (AMD) in JNJ 81201887 Parent Clinical Studies 2022-500747-21-00 — macular degeneration, atrophy, geographic atrophy | Phase 2 | Not yet recruiting | 2025 |
| A clinical trial to learn more about the effects of FWY003 in people with geographic atrophy associated with age related macular degeneration 2025-523704-77-00 — macular degeneration, safety, atrophy, geographic atrophy | Phase 2 | Not yet recruiting | 2026 |
| A study to test whether BI 764524 helps people with an eye condition called diabetic retinopathy 2023-508891-12-00 — eye, safety, diabetic retinopathy, pharmacokinetics | Phase 2 | Active not recruiting | 2024 |
| A Phase 3 Randomized Double Masked Active Controlled Trial of a Single Intravitreal Injection of 4D 150 in Adults with Macular Neovascularization Secondary to Age Related Macular Degeneration (4FRONT 2) 2025-521349-25-00 — injections, macular degeneration, intravitreal injections | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map